Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. (NYSE American: AIM) generates frequent news related to its development of immuno-pharma therapeutics, particularly its flagship product candidate Ampligen (rintatolimod). Company announcements emphasize research and development in cancers, viral diseases, immune-deficiency disorders, and cancers with unmet medical needs, as well as updates on its intellectual property portfolio and corporate actions.
News coverage for AIM ImmunoTech often focuses on clinical and scientific milestones. Recent communications describe progress in the DURIPANC clinical program, where Ampligen is evaluated in combination with AstraZeneca’s Imfinzi (durvalumab) for metastatic pancreatic cancer, and presentations of data from a completed Phase 2 study in advanced recurrent ovarian cancer combining Ampligen with cisplatin and Merck’s Keytruda (pembrolizumab). The company also highlights publications in peer-reviewed journals and abstracts accepted at major scientific meetings such as the Society for Immunotherapy of Cancer (SITC).
Another recurring theme in AIM’s news is the expansion of its intellectual property. The company has announced a European patent covering compositions of its proprietary dsRNAs, including Ampligen, for treating Long COVID, and a patent in Japan for using Ampligen with checkpoint inhibitors for cancer treatment. These updates are presented as part of AIM’s strategy to strengthen protection around Ampligen in oncology and post‑COVID indications.
Investors following AIM ImmunoTech’s news will also see items on financial and corporate developments, including stock dividends, participation in investor conferences, public offerings of common stock and warrants, and financing agreements such as a promissory note with an institutional investor. Regular news releases on quarterly financial results, capital-raising transactions, and shareholder meetings provide additional context on the company’s operations and governance.
This news page aggregates such announcements so readers can review AIM ImmunoTech’s clinical updates, patent developments, financing activities, and corporate communications in one place.
AIM ImmunoTech Inc. announced plans to enhance its corporate governance by adding two directors with expertise in biotechnology commercialization and diversity. The board's Compensation Committee will consult an independent compensation expert to review executive pay, responding to shareholder feedback on past advisory votes.
In the previous year, AIM achieved significant clinical milestones, including positive outcomes in pancreatic cancer and other studies involving its lead product, Ampligen. These advancements aim to further align leadership with shareholder interests and boost AIM's value.
AIM ImmunoTech Inc. (AIM) announced the re-election of all three directors at its Annual Meeting of Shareholders. Directors Stewart Appelrouth, Thomas Equels, and William Mitchell received unanimous support. The company expressed gratitude towards shareholders and reaffirmed its commitment to advancing its lead drug, Ampligen, into oncology for long-term shareholder value. Ampligen is currently in clinical trials for various cancers and is approved in Argentina for chronic fatigue syndrome.
AIM ImmunoTech Inc. has received FDA Orphan Drug Designation for its immuno-modulator, Ampligen® (rintatolimod), targeting Ebola virus disease. This designation acknowledges Ampligen's potential in treating rare diseases, qualifying AIM for incentives like tax credits and possible market exclusivity. Although Ebola isn't a current primary focus, previous studies show Ampligen's efficacy against various viruses, including COVID-19. The firm is conducting ongoing clinical trials to further evaluate Ampligen's applications.
AIM ImmunoTech Inc. announced that the Delaware Court of Chancery denied Jonathan Jorgl's request for a preliminary injunction regarding his attempts to nominate directors to AIM's Board. The Court found Jorgl's nomination notice misleading and non-compliant with AIM's bylaws. Consequently, Jorgl's nominations will not be recognized in the upcoming Annual Meeting set for November 3, 2022. AIM urges shareholders to support the current Board, highlighting ongoing progress in clinical trials and the company’s efforts in oncology.
AIM ImmunoTech Inc. has issued a letter to shareholders addressing misleading statements from an activist group attempting to gain control of the Board. The letter emphasizes that the group is led by Franz Tudor, a convicted felon, and funded by Michael Xirinachs, also a convicted criminal. AIM urges shareholders to support their current directors in the upcoming November 3, 2022 Annual Meeting. The Board highlights significant positive developments, including positive clinical trial results and lifting of an FDA Clinical Hold.
AIM ImmunoTech Inc. has announced the advancement of its Phase 2 study for Ampligen, targeting post-COVID conditions. Following the FDA's approval of its IND application, the enrollment for the study is set to begin in Q1 2023. This randomized, double-blind, placebo-controlled trial will evaluate the safety and efficacy of Ampligen in around 80 patients suffering from fatigue related to post-COVID conditions. Initial findings from previous studies indicate potential therapeutic benefits, highlighting the urgency to address this growing public health issue.
AIM ImmunoTech has received FDA clearance to initiate a Phase 2 study for its drug, Ampligen, targeting post-COVID conditions. The trial, expected to begin enrollment in Q1 2023, will assess the drug's effectiveness in treating symptoms like fatigue and ‘brain fog’. Approximately 80 subjects aged 18-60 will participate in this double-blind, placebo-controlled study. Initial data from previous trials suggests promising safety and efficacy. This trial aims to address significant unmet medical needs for patients suffering from debilitating post-COVID symptoms.
AIM ImmunoTech is set to host a Virtual Investor Long COVID Event on September 28, 2022, at 3:00 PM ET. The event will feature a moderated discussion with Key Opinion Leaders Dr. Charles Lapp and Dr. Daniel Peterson, focusing on the company’s FDA-authorized treatment protocol for its investigational drug, Ampligen, aimed at patients with long COVID symptoms. Investors can submit questions live during the event, and a replay will be available shortly after.
AIM ImmunoTech Inc. has made significant strides in repurposing its lead drug, Ampligen, for oncology treatments, especially over the past 18 months. The company filed its Definitive Proxy Statement ahead of its Annual Meeting on November 3, 2022, urging shareholders to support its current board against the Jorgl Activist Group. Highlights include positive interim trial results and FDA approval to proceed with a Phase 2 study for Ampligen in pancreatic cancer. AIM holds approximately $41.7 million in liquid assets, ensuring financial stability through 2023.
AIM ImmunoTech Inc. (AIM) announced that CEO Thomas K. Equels will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York and virtually from September 12-14, 2022. The event emphasizes AIM's commitment to developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19. Attendees can engage in one-on-one meetings with management. A video webcast of the presentation will be available starting September 12 at 7:00 AM ET and archived for 90 days.
FAQ
What is the current stock price of Aim Immunotech (AIM)?
What is the market cap of Aim Immunotech (AIM)?
